|
1
|
Wen C and Dehnel T: China wrestles with
lung cancer. Lancet Oncol. 12:152011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Molina JR, Yang P, Cassivi SD, Schild SE
and Adjei AA: Non-small cell lung cancer: Epidemiology, risk
factors, treatment, and survivorship. Mayo Clin Proc. 83:584–594.
2008. View
Article : Google Scholar : PubMed/NCBI
|
|
3
|
Wakelee HA, Chang ET, Gomez SL, Keegan TH,
Feskanich D, Clarke CA, Holmberg L, Yong LC, Kolonel LN, Gould MK
and West DW: Lung cancer incidence in never-smokers. J Clin Oncol.
25:472–478. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Fujii T, Dracheva T, Player A, Chacko S,
Clifford R, Strausberg RL, Buetow K, Azumi N, Travis WD and Jen J:
A preliminary transcriptome map of non-small cell lung cancer.
Cancer Res. 62:3340–3346. 2002.PubMed/NCBI
|
|
5
|
Apetoh L, Ghiringhelli F, Tesniere A,
Obeid M, Ortiz C, Criollo A, Mignot G, Maiuri MC, Ullrich E,
Saulnier P, et al: Toll-like receptor 4-dependent contribution of
the immune system to anticancer chemotherapy and radiotherapy. Nat
Med. 13:1050–1059. 2007. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bianchi ME: HMGB1 loves company. J Leukoc
Biol. 86:573–576. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Agresti A and Bianchi ME: HMGB proteins
and gene expression. Curr Opin Genet Dev. 13:170–178. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Lotze MT and Tracey KJ: High-mobility
group box 1 protein (HMGB1): Nuclear weapon in the immune arsenal.
Nat Rev Immunol. 5:331–342. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
9
|
Seong SY and Matzinger P: Hydrophobicity:
An ancient damage-associated molecular pattern that initiates
innate immune responses. Nat Rev Immunol. 4:469–478. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Foell D, Wittkowski H, Vogl T and Roth J:
S100 proteins expressed in phagocytes: A novel group of
damage-associated molecular pattern molecules. J Leukoc Biol.
81:28–37. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kaczmarek A, Vandenabeele P and Krysko DV:
Necroptosis: The release of damage-associated molecular patterns
and its physiological relevance. Immunity. 38:209–223. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Krysko DV, Agostinis P, Krysko O, Garg AD,
Bachert C, Lambrecht BN and Vandenabeele P: Emerging role of
damage-associated molecular patterns derived from mitochondria in
inflammation. Trends Immunol. 32:157–164. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ahrens S, Zelenay S, Sancho D, Hanč P,
Kjær S, Feest C, Fletcher G, Durkin C, Postigo A, Skehel M, et al:
F-actin is an evolutionarily conserved damage-associated molecular
pattern recognized by DNGR-1, a receptor for dead cells. Immunity.
36:635–645. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Rubartelli A and Lotze MT: Inside,
outside, upside down: Damage-associated molecular-pattern molecules
(DAMPs) and redox. Trends Immunol. 28:429–436. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Alvarez K and Vasquez G: Damage-associated
molecular patterns and their role as initiators of inflammatory and
auto-immune signals in systemic lupus erythematosus. Int Rev
Immunol. 36:259–270. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Land WG: The role of damage-associated
molecular patterns (DAMPs) in human diseases: Part II: DAMPs as
diagnostics, prognostics and therapeutics in clinical medicine.
Sultan Qaboos Univ Med J. 15:e157–e170. 2015.PubMed/NCBI
|
|
17
|
Laursen TL, Stoy S, Deleuran B, Vilstrup
H, Gronbaek H and Sandahl TD: The damage-associated molecular
pattern HMGB1 is elevated in human alcoholic hepatitis, but does
not seem to be a primary driver of inflammation. APMIS.
124:741–747. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Fabbri M, Garzon R, Cimmino A, Liu Z,
Zanesi N, Callegari E, Liu S, Alder H, Costinean S,
Fernandez-Cymering C, et al: MicroRNA-29 family reverts aberrant
methylation in lung cancer by targeting DNA methyltransferases 3A
and 3B. Proc Natl Acad Sci USA. 104:15805–15810. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Esquela-Kerscher A, Trang P, Wiggins JF,
Patrawala L, Cheng A, Ford L, Weidhaas JB, Brown D, Bader AG and
Slack FJ: The let-7 microRNA reduces tumor growth in mouse models
of lung cancer. Cell Cycle. 7:759–764. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Chin LJ, Ratner E, Leng S, Zhai R, Nallur
S, Babar I, Muller RU, Straka E, Su L, Burki EA, et al: A SNP in a
let-7 microRNA complementary site in the KRAS 3′ untranslated
region increases non-small cell lung cancer risk. Cancer Res.
68:8535–8540. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wiggins JF, Ruffino L, Kelnar K, Omotola
M, Patrawala L, Brown D and Bader AG: Development of a lung cancer
therapeutic based on the tumor suppressor microRNA-34. Cancer Res.
70:5923–5930. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Markou A, Tsaroucha EG, Kaklamanis L,
Fotinou M, Georgoulias V and Lianidou ES: Prognostic value of
mature microRNA-21 and microRNA-205 overexpression in non-small
cell lung cancer by quantitative real-time RT-PCR. Clin Chem.
54:1696–1704. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhang JG, Wang JJ, Zhao F, Liu Q, Jiang K
and Yang GH: MicroRNA-21 (miR-21) represses tumor suppressor PTEN
and promotes growth and invasion in non-small cell lung cancer
(NSCLC). Clin Chim Acta. 411:846–852. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Volinia S, Calin GA, Liu CG, Ambs S,
Cimmino A, Petrocca F, Visone R, Iorio M, Roldo C, Ferracin M, et
al: A microRNA expression signature of human solid tumors defines
cancer gene targets. Proc Natl Acad Sci USA. 103:2257–2261. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Liu Z, Xu Y, Long J, Guo K, Ge C and Du R:
microRNA-218 suppresses the proliferation, invasion and promotes
apoptosis of pancreatic cancer cells by targeting HMGB1. Chin J
Cancer Res. 27:247–257. 2015.PubMed/NCBI
|
|
26
|
Zhang P, Li J, Song Y and Wang X:
MiR-129-5p inhibits proliferation and invasion of chondrosarcoma
cells by regulating SOX4/Wnt/β-catenin signaling pathway. Cell
Physiol Biochem. 42:242–253. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Li D, Liu X, Lin L, Hou J, Li N, Wang C,
Wang P, Zhang Q, Zhang P, Zhou W, et al: MicroRNA-99a inhibits
hepatocellular carcinoma growth and correlates with prognosis of
patients with hepatocellular carcinoma. J Biol Chem.
286:36677–36685. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Song B, Zhang C, Li G, Jin G and Liu C:
MiR-940 inhibited pancreatic ductal adenocarcinoma growth by
targeting MyD88. Cell Physiol Biochem. 35:1167–1177. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zhou Q and Yu Y: Upregulated CDK16
expression in serous epithelial ovarian cancer cells. Med Sci
Monit. 21:3409–3414. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Li H, Xu Y, Qiu W, Zhao D and Zhang Y:
Tissue miR-193b as a novel biomarker for patients with ovarian
cancer. Med Sci Monit. 21:3929–3934. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Jiang Z, Wang H, Li Y, Hou Z, Ma N, Chen
W, Zong Z and Chen S: MiR-129-5p is down-regulated and involved in
migration and invasion of gastric cancer cells by targeting
interleukin-8. Neoplasma. 63:673–680. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Shen N, Huang X and Li J: Upregulation of
miR-129-5p affects laryngeal cancer cell proliferation,
invasiveness, and migration by affecting STAT3 expression. Tumor
Biol. 37:1789–1796. 2016. View Article : Google Scholar
|
|
33
|
Luo J, Chen J and He L: mir-129-5p
attenuates irradiation-induced autophagy and decreases
radioresistance of breast cancer cells by targeting HMGB1. Med Sci
Monit. 21:4122–4129. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Dumitriu IE, Bianchi ME, Bacci M, Manfredi
AA and Rovere-Querini P: The secretion of HMGB1 is required for the
migration of maturing dendritic cells. J Leukoc Biol. 81:84–91.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Kang R, Xie Y, Zhang Q, Hou W, Jiang Q,
Zhu S, Liu J, Zeng D, Wang H, Bartlett DL, et al: Intracellular
HMGB1 as a novel tumor suppressor of pancreatic cancer. Cell Res.
27:916–932. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Perrot I, Blanchard D, Freymond N, Isaac
S, Guibert B, Pachéco Y and Lebecque S: Dendritic cells
infiltrating human non-small cell lung cancer are blocked at
immature stage. J Immunol. 178:2763–2769. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Konishi J, Yamazaki K, Azuma M, Kinoshita
I, Dosaka-Akita H and Nishimura M: B7-H1 expression on non-small
cell lung cancer cells and its relationship with tumor-infiltrating
lymphocytes and their PD-1 expression. Clin Cancer Res.
10:5094–5100. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Kusume A, Sasahira T, Luo Y, Isobe M,
Nakagawa N, Tatsumoto N, Fujii K, Ohmori H and Kuniyasu H:
Suppression of dendritic cells by HMGB1 is associated with lymph
node metastasis of human colon cancer. Pathobiology. 76:155–162.
2009. View Article : Google Scholar : PubMed/NCBI
|
